



Zeal & Innovation in Medicine

Ref No.: ZLL/CS/BM/BSE-NSE

Date : 13.05.2024

BSE Limited, Compliance Department, P. J. Towers, Dalal Street, Mumbai – 400 001 (Scrip Code - 541400)	National Stock Exchange of India Limited, Listing Compliance Department, Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
--	---

Dear Sir,

**Sub : Outcome of Board Meeting held on 13.05.2024**

**Ref : Notice of Board Meeting dt. 06.05.2024**

In terms of Regulation 30 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today has inter-alia considered and approved:

- 1) the Audited Financial Statements (Standalone and Consolidated) of the Company for the year ended 31<sup>st</sup> March, 2024.
- 2) the Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended 31<sup>st</sup> March, 2024 (prepared pursuant to SEBI (LODR) Regulations, 2015).

Walker Chandiook & Co LLP, Chartered Accountants, the Statutory Auditors of the Company have issued auditor's report with an unmodified opinion on the financial results for the year ended 31.03.2024 which is enclosed herewith.

- 3) Investment of upto Rs. 40 Lakhs in the equity shares of SIA ZIM Laboratories Limited, wholly owned subsidiary of the Company.
- 4) Investment of upto Rs. 02.00 crores in equity shares of ZIMTAS Pty Ltd., subsidiary of the Company.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1 /P/CI R/2023/123 dated July 13, 2023 are also enclosed as Annexure I & Annexure II.

Kindly take the intimation on record.

The Board Meeting commenced at 02:30 p.m. and concluded at 08:45 p.m.

Thanking you,

Yours faithfully,

For ZIM LABORATORIES LIMITED

(Piyush Nikhade)  
Company Secretary and Compliance Officer

**ZIM LABORATORIES LIMITED**

[www.zimlab.in](http://www.zimlab.in) | [info@zimlab.in](mailto:info@zimlab.in) | CIN : L99999MH1984PLC032172

---

**Walker Chandiook & Co LLP**

16th Floor, Tower III,  
One International Center,  
S B Marg, Prabhadevi (W),  
Mumbai - 400013  
Maharashtra, India  
T +91 22 6626 2699  
F +91 22 6626 2601

## **Independent Auditor's Report on Consolidated Annual Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of ZIM Laboratories Limited**

### **Opinion**

1. We have audited the accompanying consolidated annual financial results ('the Statement') of **ZIM Laboratories Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') for the year ended **31 March 2024**, attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of other auditors on separate/consolidated audited financial statements/ financial information of the subsidiaries, as referred to in paragraph 12 below, the Statement:
  - (i) includes the annual financial results of the entities listed in Annexure 1;
  - (ii) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations; and
  - (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the consolidated net profit after tax and other comprehensive income and other financial information of the Group, for the year ended 31 March 2024.

### **Basis for Opinion**

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us together with the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph 12 of the Other Matter section below, is sufficient and appropriate to provide a basis for our opinion.

**ZIM Laboratories Limited**

**Independent Auditor's Report on Consolidated Annual Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

---

**Responsibilities of Management and Those Charged with Governance for the Statement**

4. The Statement, which is the responsibility of the Holding Company's management and has been approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the consolidated net profit and other comprehensive income, and other financial information of the Group in accordance with the Ind AS prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Holding Company's Board of Directors is also responsible for ensuring accuracy of records including financial information considered necessary for the preparation of the Statement. Further, in terms of the provisions of the Act, the respective Board of Directors of the companies included in the Group, covered under the Act are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Group, and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively, for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results, that give a true and fair view and are free from material misstatement, whether due to fraud or error. These financial results have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.
5. In preparing the Statement, the respective Board of Directors of the companies included in the Group, are responsible for assessing the ability of the Group, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the respective Board of Directors either intends to liquidate such Company or to cease operations, or has no realistic alternative but to do so.
6. Those respective Board of Directors are also responsible for overseeing the financial reporting process of the companies included in the Group.

**Auditor's Responsibilities for the Audit of the Statement**

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act will always detect a material misstatement, when it exists. Misstatements can arise from fraud or error, and are considered material if, individually, or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

**ZIM Laboratories Limited**

**Independent Auditor's Report on Consolidated Annual Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

---

8. As part of an audit in accordance with the Standards on Auditing specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
  - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls;
  - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;
  - Conclude on the appropriateness of Board of Directors's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group, to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern;
  - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation; and
  - Obtain sufficient appropriate audit evidence regarding the financial results/ financial information/ financial statements of the entities within the Group, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement, of which we are the independent auditors. For the other entities included in the Statement, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.
9. We communicate with those charged with governance of the Holding Company and such other entities included in the Statement, of which we are the independent auditors, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**ZIM Laboratories Limited**

**Independent Auditor's Report on Consolidated Annual Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

---

11. We also performed procedures in accordance with SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019, issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

**Other Matters**

12. We did not audit the annual financial statements/ consolidated financial statements/ financial information of four subsidiaries included in the Statement, whose financial statements/ consolidated financial statements/ financial information (before eliminating inter company balances/transactions) reflects total assets of ₹ 2,362.76 lakhs as at 31 March 2024, total revenues of ₹ 2,409.21 lakhs, total net profit after tax of ₹ 51.42 lakhs, total comprehensive income of ₹ Nil, and cash flows(net) of ₹ 404.53 lakhs for the year ended on that date, as considered in the Statement. These annual financial statements/ consolidated financial statements / financial information have been audited by other auditors/ Independent firm of Chartered Accountants and whose audit reports have been furnished to us by the management, and our opinion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries are based solely on the audit reports of such other auditors/Independent firm of Chartered Accountants, and the procedures performed by us as stated in paragraph 11 above.

Our opinion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors/ Independent firm of Chartered Accountants.

13. The Statement includes the consolidated financial results for the quarter ended 31 March 2024, being the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year-to-date consolidated figures up to the third quarter of the current financial year, which were subjected to a limited review by us.

For **Walker Chandiook & Co LLP**

Chartered Accountants

Firm Registration No:001076N/N500013

**KHUSHROO** Digitally signed by  
KHUSHROO B PANTHAKY  
**B PANTHAKY** Date: 2024.05.13 17:38:54  
+05'30'

**Khushroo B. Panthaky**

Partner

Membership No:042423

**UDIN:24042423BKC MNQ1786**

Place: Mumbai

Date: 13 May 2024

**ZIM Laboratories Limited**

**Independent Auditor's Report on Consolidated Annual Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

---

**Annexure 1**

**List of entities included in the Statement**

**Subsidiary companies**

1. ZIM Laboratories FZE
2. ZIM Health Technologies Limited
3. SIA ZIM Laboratories Limited
4. ZIM Thinorals Private Limited
5. ZIMTAS PTY Limited, Australia (w.e.f. 5 March 2024)
6. ZIM Laboratories Middle East DMCC (w.e.f. 28 September 2023)



**ZIM Laboratories Limited**

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India  
CIN:L99999MH1984PLC032172, Website: www.ZIMlab.in

**A. STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31 MARCH 2024**

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Year ended	
		31.03.2024	31.12.2023	31.03.2023	31.03.2024	31.03.2023
		(Unaudited) (Refer Note 5)	(Unaudited)	(Unaudited) (Refer Note 5)	(Audited)	(Audited)
1	<b>Income</b>					
	a) Revenue from operations	11,786.28	9,629.26	10,541.06	36,742.44	39,852.71
	b) Other income	153.47	111.23	69.44	518.39	641.32
	<b>Total income</b>	<b>11,939.75</b>	<b>9,740.49</b>	<b>10,610.50</b>	<b>37,260.83</b>	<b>40,494.03</b>
2	<b>Expenses</b>					
	a) Cost of materials consumed	5,348.58	5,150.89	4,413.54	17,769.83	16,498.32
	b) Purchases of stock-in-trade	211.83	300.65	138.51	779.61	1,739.16
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	58.65	(1,029.92)	404.51	(1,405.32)	1,646.35
	d) Employee benefits	1,471.19	1,317.12	1,339.64	5,334.27	4,931.82
	e) Finance costs	227.71	169.62	126.96	692.44	557.54
	f) Depreciation and amortisation	390.53	393.54	493.01	1,595.18	1,746.90
	g) Other expenses	3,131.30	2,737.19	2,699.92	10,130.58	9,838.44
	<b>Total expenses</b>	<b>10,839.79</b>	<b>9,039.09</b>	<b>9,616.09</b>	<b>34,896.59</b>	<b>36,958.53</b>
3	<b>Profit before tax (1-2)</b>	<b>1,099.96</b>	<b>701.40</b>	<b>994.41</b>	<b>2,364.24</b>	<b>3,535.50</b>
4	<b>Tax expense</b>					
	Current Tax	(128.73)	134.98	156.49	94.15	629.09
	Deferred Tax	420.13	87.96	114.28	545.46	462.96
	<b>Total tax expense</b>	<b>291.40</b>	<b>222.94</b>	<b>270.77</b>	<b>639.61</b>	<b>1,092.05</b>
5	<b>Profit after tax (3-4)</b>	<b>808.56</b>	<b>478.46</b>	<b>723.64</b>	<b>1,724.63</b>	<b>2,443.45</b>
6	<b>Other comprehensive income - profit/(loss)</b>					
	a) Items that will not be reclassified to profit or loss	(5.03)	(16.28)	(69.96)	(53.88)	(65.13)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	1.47	4.74	20.38	15.69	18.97
	c) Items that may be reclassified to profit or loss	(3.50)	7.33	(11.17)	13.29	113.86
	d) Tax (expense)/credit on the items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Other comprehensive income (net of tax) - profit/(loss)</b>	<b>(7.06)</b>	<b>(4.21)</b>	<b>(60.75)</b>	<b>(24.90)</b>	<b>67.70</b>
7	<b>Total comprehensive income (5+6)</b>	<b>801.50</b>	<b>474.25</b>	<b>662.89</b>	<b>1,699.73</b>	<b>2,511.15</b>
8	<b>Net Profit after tax attributable to</b>					
	Owners	808.57	478.46	723.64	1,724.64	2,443.45
	Non-controlling interest	(0.01)	-	-	(0.01)	-
9	<b>Other comprehensive Income attributable to</b>					
	Owners	(7.06)	(4.21)	(60.75)	(24.90)	67.70
	Non-controlling interest	-	-	-	-	-
10	<b>Total Comprehensive Income attributable to</b>					
	Owners	801.51	474.25	662.89	1,699.74	2,511.15
	Non-controlling interest	(0.01)	-	-	(0.01)	-
11	Paid-up equity share capital (face value of Rs. 10/- each)	4,872.58	4,872.58	4,872.58	4,872.58	4,872.58
12	Other equity (revaluation reserve : Rs. Nil)				19,002.00	15,162.02
13	Earnings per share (face value of Rs. 10/- each) (not annualised for the quarters) ( Rs. )					
	Basic	1.66	0.98	1.48	3.54	5.01
	Diluted	1.66	0.98	1.48	3.54	5.01



**B. Consolidated Balance Sheet**

	As at 31.03.2024 Rs. in lakhs (Audited)	As at 31.03.2023 Rs. in lakhs (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	15,693.35	10,372.07
Capital work-in-progress	2,351.60	1,783.85
Goodwill on consolidation	16.94	16.94
Other intangible assets	372.34	476.79
Intangible assets under development	1,876.68	915.27
Financial Assets		
Investments	5.15	5.15
Other financial assets	78.55	91.67
Non-current tax assets (net)	386.78	222.49
Other non-current assets	1,135.99	1,178.83
	<b>21,917.38</b>	<b>15,063.06</b>
<b>Current assets</b>		
Inventories	8,126.29	5,370.62
Financial Assets		
Trade receivables	10,016.54	9,524.87
Cash and cash equivalents	960.02	642.05
Bank balances other than cash and cash equivalents	86.38	109.80
Other financial assets	31.85	14.23
Other current assets	3,543.77	3,433.23
	<b>22,764.85</b>	<b>19,094.80</b>
<b>TOTAL ASSETS</b>	<b>44,682.23</b>	<b>34,157.86</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	4,872.58	4,872.58
Other equity (Refer Note 4)	19,002.00	15,162.02
<b>Equity attributable to equity holders of the parent</b>	<b>23,874.58</b>	<b>20,034.60</b>
Non controlling interest	0.03	-
<b>Total equity</b>	<b>23,874.61</b>	<b>20,034.60</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial Liabilities		
Borrowings	3,560.06	2,462.45
Other financial liabilities	294.95	101.78
Deferred tax liabilities (net)	1,010.09	480.32
	<b>4,865.10</b>	<b>3,044.55</b>
<b>Current liabilities</b>		
Financial Liabilities		
Borrowings	7,075.20	3,494.36
Lease Liabilities	247.18	157.22
Trade payables		
-total outstanding due of micro enterprises and small enterprises	6.31	232.97
-total outstanding due of creditors other than micro enterprises and small enterprises	6,231.78	5,590.93
Other financial liabilities	1,077.72	838.62
Other current liabilities	1,224.65	705.12
Provisions	79.68	59.49
	<b>15,942.52</b>	<b>11,078.71</b>
<b>TOTAL LIABILITIES</b>	<b>20,807.62</b>	<b>14,123.26</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>44,682.23</b>	<b>34,157.86</b>





### C. Consolidated Cash Flow Statement

	Year ended 31.03.2024 Rs. in lakhs (Unaudited)	Year ended 31.03.2023 Rs. in lakhs (Unaudited)
<b>Cash flow from operating activities</b>		
<b>Profit before tax</b>	<b>2,364.24</b>	<b>3,535.50</b>
Depreciation and amortisation expense	1,595.18	1,746.90
Government Incentive	(9.26)	(8.20)
Interest on Lease deposits	(4.55)	(9.21)
(Gain) on sale of property, plant and equipment (net)	(46.97)	(2.00)
Property, plant and equipment written off	-	65.97
Unrealized Foreign Exchange (Gain)	(113.98)	(101.76)
Provision for employee benefits	(0.04)	(105.46)
Dividend income on investments	(0.60)	(0.60)
Interest income	(4.29)	(6.82)
Bad debts Written off	110.07	-
Loss allowance - trade receivables	(17.47)	79.14
Finance costs	692.44	557.54
<b>Operating profit before working capital changes</b>	<b>4,564.77</b>	<b>5,751.00</b>
Movement in working capital :		
Increase/(decrease) in trade and other payables	790.81	(3,646.59)
(Increase)/decrease in inventories	(2,755.67)	2,157.80
(Increase)/decrease in trade and other receivables	(713.65)	269.46
<b>Net Cash generated from operations</b>	<b>1,886.26</b>	<b>4,531.67</b>
Direct taxes paid (net of refunds)	(258.44)	(714.85)
<b>Net cash from operating activities (A)</b>	<b>1,627.82</b>	<b>3,816.82</b>
<b>Cash flow from investing activities</b>		
Purchases of property, plant and equipment and intangibles (Refer Note i)	(7,392.32)	(3,666.79)
Sale proceeds of property, plant and equipment	54.81	2.00
Deposits placed with bank (having original maturity of more than three months)	(28.39)	-
Maturity of bank deposits (having original maturity of more than three months)	59.71	35.99
Interest received	4.33	7.85
Dividend received	0.60	0.60
<b>Net cash (used in) investing activities (B)</b>	<b>(7,301.26)</b>	<b>(3,620.35)</b>
<b>Cash flow from financing activities</b>		
Transaction cost for issue of bonus shares	-	(47.50)
Deemed equity contribution from shareholder (net) (Refer Note 4)	2,140.24	-
Proceeds from long term borrowings	2,814.69	1,835.30
(Repayment) of long term borrowings	(1,293.25)	(1,547.08)
Proceeds of short term borrowings (net)	3,215.47	559.16
(Repayment) of principal portion of lease obligations	(172.39)	(191.97)
Finance costs paid	(751.36)	(553.35)
Changes in unclaimed dividend bank balances	4.93	5.85
Dividends paid on equity shares (including unclaimed)	(4.93)	(5.85)
<b>Net cash generated from financing activities (C)</b>	<b>5,953.40</b>	<b>54.56</b>
<b>Effects of exchange rate changes on cash and cash equivalents (D)</b>	<b>38.01</b>	<b>48.99</b>
Net increase in cash and cash equivalents (A+B+C+D)	317.97	300.02
Opening cash and cash equivalents	642.05	342.03
<b>Closing cash and cash equivalents</b>	<b>960.02</b>	<b>642.05</b>
<b>Components of cash and cash equivalents</b>		
Cash on hand	11.76	8.02
Balances with banks in:		
- Current accounts	948.26	634.03
<b>Total Cash and cash equivalents</b>	<b>960.02</b>	<b>642.05</b>

Note (i) Includes capital work-in-progress, capital advance, payables for property, plant and equipment, intangibles assets and intangible assets under development.

Note (ii) The Statement of Cashflow has been prepared under the indirect method as set out in Indian Accounting Standard (Ind AS 7) Statement of Cash flows



**Notes (A to C):**

- 1) The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13 May 2024. There are no qualifications in the audit report issued for the year ended 31 March 2024.
- 2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The Company and its subsidiaries are principally engaged in a single business segment which is "pharmaceuticals".
- 4) The Holding Company had entered into an escrow agreement in 2017 (with subsequent renewals) with one of its shareholders, wherein the shareholder had provided his holdings to the extent of 30 Lakhs equity shares (including 25 Lakhs bonus shares) as a security towards realization of covered trade receivables. During the year, the equity shares have been liquidated at a gross consideration of Rs. 3,067.58 lakhs. Accordingly, the net amount realised (which is gross consideration as reduced by the applicable taxes and charges) has been recognised as a credit to the 'Retained Earnings' under 'Other equity' in accordance with the guidance under Ind AS 1- Presentation of Financial Statements, which states that transactions with shareholders (being the owners of Holding Company), shall be recognized under Equity.
- 5) The figures for the quarter ended 31 March 2024 and 31 March 2023 represent the balance between audited figures in respect of the full financial years and those published till the third quarter of the respective financial years, which were subjected to a limited review by the statutory auditor.
- 6) During the current quarter, the Holding Company has made an investment in the equity shares of its subsidiary, "ZIMTAS PTY Limited", which was incorporated during the year ended 31 March 2024 in Australia.
- 7) Figures of previous period/year have been regrouped/rearranged wherever necessary. The impact of the same is not material to the users of financial statement.

**Place: Nagpur**  
**Date: 13 May 2024**

**ANWAR**  
**SIRAJ DAUD**

Digitaly signed by ANWAR SIRAJ DAUD  
DN: c=IN, postalCode=441002, serialNumber=1776, street=ANWAR SIRAJ DAUD, o=ANWAR SIRAJ DAUD, ou=ANWAR SIRAJ DAUD, email=ANWAR SIRAJ DAUD, cn=ANWAR SIRAJ DAUD  
Date: 2024.05.13 11:40:27 +05'30'

**Anwar S. Daud**  
**Managing Director**



---

**Walker Chandiook & Co LLP**

16th Floor, Tower III,  
One International Center,  
S B Marg, Prabhadevi (W),  
Mumbai - 400013  
Maharashtra, India  
T +91 22 6626 2699  
F +91 22 6626 2601

## **Independent Auditor's Report on Standalone Annual Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of ZIM Laboratories Limited**

### **Opinion**

1. We have audited the accompanying standalone annual financial results ('the Statement') of **ZIM Laboratories Limited** ('the Company') for the year ended **31 March 2024**, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
  - (i) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations; and
  - (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act'), read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company for the year ended 31 March 2024.

### **Basis for Opinion**

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.

## **ZIM Laboratories Limited**

### **Independent Auditor's Report on Standalone Annual Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

---

#### **Responsibilities of Management and Those Charged with Governance for the Statement**

4. This Statement has been prepared on the basis of the standalone annual financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the Ind AS specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
5. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Statement**

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing, specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
  - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
  - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place an adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls;

**ZIM Laboratories Limited**

**Independent Auditor's Report on Standalone Annual Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

---

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;
  - Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and
  - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other Matter**

11. The Statement includes the financial results for the quarter ended 31 March 2024, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us.

For **Walker Chandiook & Co LLP**  
Chartered Accountants  
Firm Registration No:001076N/N500013

**KHUSHROO** Digitally signed by  
**B PANTHAKY** KHUSHROO B PANTHAKY  
Date: 2024.05.13 17:37:45  
+05'30'

**Khushroo B. Panthaky**  
Partner  
Membership No:042423

**UDIN:24042423BKCMNP1889**

Place: Mumbai  
Date: 13 May 2024



**ZIM Laboratories Limited**

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India  
CIN:L99999MH1984PLC032172, Website: www.zimlab.in

**A. STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31 MARCH 2024**

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Year ended	
		31.03.2024	31.12.2023	31.03.2023	31.03.2024	31.03.2023
		(Unaudited) Refer Note 3	(Unaudited)	(Unaudited) Refer Note 3	(Audited)	(Audited)
1	<b>Income</b>					
	a) Revenue from operations	11,738.72	9,581.94	10,444.85	36,547.32	39,653.13
	b) Other income	153.12	110.60	69.84	469.10	643.06
	<b>Total income</b>	<b>11,891.84</b>	<b>9,692.54</b>	<b>10,514.69</b>	<b>37,016.42</b>	<b>40,296.19</b>
2	<b>Expenses</b>					
	a) Cost of materials consumed	5,348.58	5,150.89	4,413.54	17,769.83	16,498.32
	b) Purchases of stock-in-trade	211.83	300.65	138.51	779.61	1,739.16
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	58.65	(1,029.92)	404.51	(1,405.32)	1,646.35
	d) Employee benefits	1,411.97	1,232.17	1,302.61	5,081.03	4,647.00
	e) Finance costs	227.71	169.62	126.96	692.44	557.54
	f) Depreciation and amortisation	387.48	357.80	457.80	1,482.93	1,612.83
	g) Other expenses	3,165.31	2,810.38	2,680.61	10,311.93	10,003.19
	<b>Total expenses</b>	<b>10,811.53</b>	<b>8,991.59</b>	<b>9,524.54</b>	<b>34,712.45</b>	<b>36,704.39</b>
3	<b>Profit before tax (1-2)</b>	<b>1,080.31</b>	<b>700.95</b>	<b>990.15</b>	<b>2,303.97</b>	<b>3,591.80</b>
4	<b>Tax expense</b>					
	Current Tax	(128.85)	129.96	161.90	82.96	627.96
	Deferred Tax	420.13	87.96	114.28	545.46	462.96
	<b>Total tax expense</b>	<b>291.28</b>	<b>217.92</b>	<b>276.18</b>	<b>628.42</b>	<b>1,090.92</b>
5	<b>Profit after tax (3-4)</b>	<b>789.03</b>	<b>483.03</b>	<b>713.97</b>	<b>1,675.55</b>	<b>2,500.88</b>
6	<b>Other comprehensive income - profit/(loss)</b>					
	a) Items that will not be reclassified to profit or loss	(5.03)	(16.28)	(69.96)	(53.88)	(65.13)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	1.47	4.74	20.38	15.69	18.97
	<b>Other comprehensive income (net of tax) - profit/(loss)</b>	<b>(3.56)</b>	<b>(11.54)</b>	<b>(49.58)</b>	<b>(38.19)</b>	<b>(46.16)</b>
7	<b>Total comprehensive income (5+6)</b>	<b>785.47</b>	<b>471.49</b>	<b>664.39</b>	<b>1,637.36</b>	<b>2,454.72</b>
8	Paid-up equity share capital (face value of Rs. 10/- each)	4,872.58	4,872.58	4,872.58	4,872.58	4,872.58
9	Other equity (revaluation reserve : Rs. Nil)				18,322.84	14,545.24
10	Earnings per share (face value of Rs. 10/- each) (not annualised for quarters) ( Rs. )					
	Basic	1.62	0.99	1.46	3.44	5.13
	Diluted	1.62	0.99	1.46	3.44	5.13



**B. Standalone Balance Sheet**

	As at 31.03.2024 Rs. in lakhs (Audited)	As at 31.03.2023 Rs. in lakhs (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	15,691.89	10,369.03
Capital work-in-progress	2,351.60	1,783.85
Intangible assets	357.43	346.22
Intangible assets under development	1,673.11	842.05
Financial Assets		
Investment in subsidiaries	817.81	812.44
Other Investments	5.15	5.15
Other financial assets	78.30	91.42
Non-current tax assets (net)	367.43	193.56
Other non-current assets	1,135.99	1,178.83
	<b>22,478.71</b>	<b>15,622.55</b>
<b>Current assets</b>		
Inventories	8,126.29	5,370.62
Financial Assets		
Trade receivables	10,009.25	8,836.35
Cash and cash equivalents	17.35	110.98
Bank balances other than cash and cash equivalents	57.99	109.80
Other financial assets	31.85	14.23
Other current assets	3,528.59	3,422.07
	<b>21,771.32</b>	<b>17,864.05</b>
<b>TOTAL ASSETS</b>	<b>44,250.03</b>	<b>33,486.60</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	4,872.58	4,872.58
Other equity (Refer Note 5)	18,322.84	14,545.24
	<b>23,195.42</b>	<b>19,417.82</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial Liabilities		
Borrowings	3,560.06	2,462.45
Lease Liabilities	294.95	101.78
Deferred tax liabilities (net)	1,010.09	480.32
	<b>4,865.10</b>	<b>3,044.55</b>
<b>Current liabilities</b>		
Financial Liabilities		
Borrowings	7,075.20	3,494.36
Lease Liabilities	247.18	157.22
Trade payables		
-total outstanding due of micro enterprises and small enterprises	6.31	232.97
-total outstanding due of creditors other than micro enterprises and small enterprises	6,260.15	5,695.12
Other financial liabilities	1,063.51	776.04
Other current liabilities	1,457.48	609.03
Provisions	79.68	59.49
	<b>16,189.51</b>	<b>11,024.23</b>
<b>TOTAL LIABILITIES</b>	<b>21,054.61</b>	<b>14,068.78</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>44,250.03</b>	<b>33,486.60</b>



### C. Standalone Cash Flow Statement

	Year ended 31.03.2024 Rs. in lakhs (Audited)	Year ended 31.03.2023 Rs. in lakhs (Audited)
<b>Cash flow from operating activities</b>		
<b>Profit before tax</b>	<b>2,303.97</b>	<b>3,591.80</b>
Depreciation and amortisation expense	1,482.93	1,612.83
Government Incentive	(9.26)	(8.20)
Interest on Lease deposits	(4.55)	(9.21)
(Gain) on sale of property, plant and equipment (net)	(0.19)	(2.00)
Property, plant and equipment written off	-	65.97
Unrealized foreign exchange (Gain)	(113.98)	(101.76)
Provision for employee benefits	(0.04)	(105.46)
Dividend income on investments	(0.60)	(0.60)
Interest income	(3.18)	(6.82)
Bad debts written off	110.07	-
Loss allowance - trade receivables	(17.47)	79.14
Finance costs	692.44	557.54
<b>Operating profit before working capital changes</b>	<b>4,440.14</b>	<b>5,673.23</b>
Movement in working capital :		
Increase (decrease)in trade and other payables	1,117.00	(3,705.66)
(Increase)/decrease in inventories	(2,755.67)	2,157.80
(Increase)/decrease in trade and other receivables	(1,397.44)	96.03
<b>Net Cash generated from operations</b>	<b>1,404.03</b>	<b>4,221.40</b>
Direct taxes paid (net of refunds)	(256.83)	(698.22)
<b>Net cash from operating activities (A)</b>	<b>1,147.20</b>	<b>3,523.18</b>
<b>Cash flow from investing activities</b>		
Purchases of property, plant and equipment and intangibles (Refer Note i)	(7,259.31)	(3,567.42)
Sale proceeds of property, plant and equipment	6.92	2.00
Investment in subsidiary	(5.37)	-
Maturity of bank deposits (having original maturity of more than three months)	59.71	35.99
Interest received	3.22	7.85
Dividend received	0.60	0.60
<b>Net cash (used in) investing activities (B)</b>	<b>(7,194.23)</b>	<b>(3,520.98)</b>
<b>Cash flow from financing activities</b>		
Transaction cost for issue of bonus shares	-	(47.50)
Deemed equity contribution from shareholder (net) (Refer Note 5)	2,140.24	-
Proceeds from long term borrowings	2,814.69	1,835.30
(Repayment) of long term borrowings	(1,293.25)	(1,547.08)
Proceeds of short term borrowings (net)	3,215.47	559.16
(Repayment) of principal portion of lease obligations	(172.39)	(191.97)
Finance costs paid	(751.36)	(553.35)
Changes in unclaimed dividend bank balances	4.93	5.85
Dividends paid on equity shares (unclaimed)	(4.93)	(5.85)
<b>Net cash generated from financing activities (C)</b>	<b>5,953.40</b>	<b>54.56</b>
Net (decrease)/increase in cash and cash equivalents (A+B+C)	(93.63)	56.76
Opening cash and cash equivalents	110.98	54.22
<b>Closing cash and cash equivalents</b>	<b>17.35</b>	<b>110.98</b>
<b>Components of cash and cash equivalents</b>		
Cash on hand	11.75	8.02
Balances with banks in:		
- Current accounts	5.60	102.96
<b>Total Cash and cash equivalents</b>	<b>17.35</b>	<b>110.98</b>

Note (i) Includes capital work-in-progress, capital advance, payables for property, plant and equipment, intangibles assets and intangible assets under development.

Note (ii) The Statement of Cash flow has been prepared under the indirect method as set out in Indian Accounting Standard (Ind AS 7) Statement of Cash flows



**Notes (A to C):**

- 1) The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13 May 2024. There are no qualifications in the audit report issued for the year ended 31 March 2024.
- 2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The figures for the quarters ended 31 March 2024 and 31 March 2023 are the balancing figures between the audited figures for the years ended as on that date and the year to date figures upto the end of third quarter of the respective financial years, on which auditors had performed a limited review.
- 4) The Company is principally engaged in a single business segment which is "pharmaceuticals".
- 5) The Company had entered into an escrow agreement in 2017 (with subsequent renewals) with one of its shareholders, wherein the shareholder had provided his holdings to the extent of 30 Lakhs equity shares (including 25 Lakhs bonus shares) as a security towards realization of covered trade receivables. During the year, the equity shares have been liquidated at a gross consideration of Rs. 3,067.58 lakhs. Accordingly, the net amount realised (which is gross consideration as reduced by the applicable taxes and charges) has been recognised as a credit to the 'Retained Earnings' under 'Other equity' in accordance with the guidance under Ind AS 1- Presentation of Financial Statements, which states that transactions with shareholders (being the owners of Company), shall be recognized under Equity.
- 6) Figures of previous period/year have been regrouped/rearranged wherever necessary. The impact of the same is not material to the users of financial statement.

Place: Nagpur  
Date: 13 May 2024

**ANWAR  
SIRAJ  
DAUD**

**Anwar S. Daud  
Managing Director**

Digitally signed by ANWAR SIRAJ DAUD  
DN: cn=N, postalCode=440002, st=MAHARASHTRA,  
streetName=NAGPURPOSTOFFICE AGARWADA HIGH SCHOOL,  
SHANTI NAGARDAUD COMPOUND 440002,  
h=NAGPUR, o=Personal, ou=9918,  
serialNumber=E2326251d66f8d9f3b73ebbc5d  
6ca315f8e718871126c23660d6c,  
pseudoemail=9140202212091944396,  
2.5.4.20=51623603d6e812337d09f68f7e7d9509  
5b84c197636a6c62f6d,  
email=ANWAR.DAUD@ZMAIL.IN, ou=ANWAR SIRAJ  
DAUD  
Date: 2024.05.13 17:21:00 +05'30'





Zeal & Innovation in Medicine

**Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1 /P/CI R/2023/123 dated July 13, 2023:**

**Annexure I**

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Entity Name: SIA ZIM Laboratories Limited. The Company was incorporated in September, 2019.  Turnover: NIL (As the Company is yet to commence the operations)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length”	The said transaction is between the Company and SIA ZIM Laboratories Limited, wholly owned subsidiary and hence a Related Party Transaction.  The transaction will be at arm’s length basis.  Mr. Zulfiquar Kamal, one of the Promoters of the Company is appointed as Directors on the Board of SIA ZIM Laboratories Limited. Except this none of the Promoters have any interest in SIA ZIM Laboratories Limited.
3	Industry to which the entity being acquired belongs	Pharmaceuticals
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The investment is with an objective of expansion and development of business in the European Regions (Regulated Markets).
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable
6	Indicative time period for completion of the acquisition	Not Applicable

**ZIM LABORATORIES LIMITED**

[www.zimlab.in](http://www.zimlab.in) | [info@zimlab.in](mailto:info@zimlab.in) | CIN : L99999MH1984PLC032172



Zeal & Innovation in **M**edicine

7	Nature of consideration – whether cash consideration or share swap and details of the same	Cash Consideration
8	Cost of acquisition or the price at which the shares are acquired	Company will invest upto Rs. 40 Lakhs in the equity shares of SIA ZIM Laboratories Limited.
9	Percentage of shareholding /control acquired and / or number of shares acquired	With the proposed investment, the Company's shareholding in SIA ZIM Laboratories Limited remains at 100%.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	SIA ZIM Laboratories Limited was incorporated in Latvia, Europe in September, 2019 to operate in Pharmaceutical Industry. The Company is under the process of registering products in various European countries.

## ZIM LABORATORIES LIMITED

[www.zimlab.in](http://www.zimlab.in) | [info@zimlab.in](mailto:info@zimlab.in) | CIN : L99999MH1984PLC032172



Zeal & Innovation in Medicine

**Annexure II**

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Entity Name: ZIMTAS PTY LTD The Company was incorporated in December, 2022.  Turnover: NIL (As the Company is yet to commence the operations)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length”	The said transaction is between the Company and ZIMTAS Pty Ltd, subsidiary of the Company and hence a Related Party Transaction.  The transaction will be at arm’s length basis.  Dr. Anwar Daud and Mr. Zulfiquar Kamal, Promoters of the Company are appointed as Directors on the Board of ZIMTAS Pty Ltd.
3	Industry to which the entity being acquired belongs	Pharmaceuticals
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The Investment is with an objective of Business Development in Australian and New Zealand markets.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable
6	Indicative time period for completion of the acquisition	Not Applicable
7	Nature of consideration – whether cash consideration or share swap and details of the same	Cash Consideration
8	Cost of acquisition or the price at which the shares are acquired	Company will invest upto Rs. 02.00 crores in the share capital of ZIMTAS Pty Ltd.
9	Percentage of shareholding /control acquired and / or number of shares acquired	With the proposed investment, the Company’s shareholding in ZIMTAS Pty Ltd. will change from

**ZIM LABORATORIES LIMITED**

[www.zimlab.in](http://www.zimlab.in) | [info@zimlab.in](mailto:info@zimlab.in) | CIN : L99999MH1984PLC032172



Zeal & Innovation in **M**edicine

		99% to 99.97%.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	ZIMTAS Pty Ltd was incorporated in Australia in December, 2022 to operate in Pharmaceutical Industry and is yet to commence its business operations.

## ZIM LABORATORIES LIMITED

[www.zimlab.in](http://www.zimlab.in) | [info@zimlab.in](mailto:info@zimlab.in) | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur  
Maharashtra, India. Ph. + 91.7118.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,  
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960